Dexmedetomidine for Sedation during Withdrawal of Support

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Agents used to control end-of-life suffering are associated with troublesome side effects. The use of dexmedetomidine for sedation during withdrawal of support in pediatrics is not yet described. An adolescent female with progressive and irreversible pulmonary deterioration was admitted. Despite weeks of therapy, she did not tolerate weaning of supplemental oxygen or continuous bilevel positive airway pressure. Given her condition and the perception that she was suffering, the family requested withdrawal of support. Despite opioids and benzodiazepines, she appeared to be uncomfortable after support was withdrawn. Ketamine was initiated. Relief from ketamine was brief, and its use was associated with a “wide-eyed” look that was distressing to the family. Ketamine was discontinued and a dexmedetomidine infusion was initiated. The patient's level of comfort improved greatly. The child died peacefully 24 hours after initiating dexmedetomidine from her underlying disease rather than the effects of the sedative.

Original languageEnglish (US)
Pages (from-to)15-18
Number of pages4
JournalPalliative Care
Volume9
DOIs
StatePublished - Jan 24 2017

Fingerprint

Dexmedetomidine
Ketamine
Continuous Positive Airway Pressure
Weaning
Hypnotics and Sedatives
Benzodiazepines
Psychological Stress
Opioid Analgesics
Pediatrics
Oxygen
Lung
Therapeutics

All Science Journal Classification (ASJC) codes

  • Advanced and Specialized Nursing

Cite this

@article{430067c33df24fb6a77726c34d412d0c,
title = "Dexmedetomidine for Sedation during Withdrawal of Support",
abstract = "Agents used to control end-of-life suffering are associated with troublesome side effects. The use of dexmedetomidine for sedation during withdrawal of support in pediatrics is not yet described. An adolescent female with progressive and irreversible pulmonary deterioration was admitted. Despite weeks of therapy, she did not tolerate weaning of supplemental oxygen or continuous bilevel positive airway pressure. Given her condition and the perception that she was suffering, the family requested withdrawal of support. Despite opioids and benzodiazepines, she appeared to be uncomfortable after support was withdrawn. Ketamine was initiated. Relief from ketamine was brief, and its use was associated with a “wide-eyed” look that was distressing to the family. Ketamine was discontinued and a dexmedetomidine infusion was initiated. The patient's level of comfort improved greatly. The child died peacefully 24 hours after initiating dexmedetomidine from her underlying disease rather than the effects of the sedative.",
author = "Christopher O'Hara and Robert Tamburro and Gary Ceneviva",
year = "2017",
month = "1",
day = "24",
doi = "10.4137/PCRT.S27954",
language = "English (US)",
volume = "9",
pages = "15--18",
journal = "Palliative Care",
issn = "1178-2242",
publisher = "Libertas Academica Ltd.",

}

Dexmedetomidine for Sedation during Withdrawal of Support. / O'Hara, Christopher; Tamburro, Robert; Ceneviva, Gary.

In: Palliative Care, Vol. 9, 24.01.2017, p. 15-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dexmedetomidine for Sedation during Withdrawal of Support

AU - O'Hara, Christopher

AU - Tamburro, Robert

AU - Ceneviva, Gary

PY - 2017/1/24

Y1 - 2017/1/24

N2 - Agents used to control end-of-life suffering are associated with troublesome side effects. The use of dexmedetomidine for sedation during withdrawal of support in pediatrics is not yet described. An adolescent female with progressive and irreversible pulmonary deterioration was admitted. Despite weeks of therapy, she did not tolerate weaning of supplemental oxygen or continuous bilevel positive airway pressure. Given her condition and the perception that she was suffering, the family requested withdrawal of support. Despite opioids and benzodiazepines, she appeared to be uncomfortable after support was withdrawn. Ketamine was initiated. Relief from ketamine was brief, and its use was associated with a “wide-eyed” look that was distressing to the family. Ketamine was discontinued and a dexmedetomidine infusion was initiated. The patient's level of comfort improved greatly. The child died peacefully 24 hours after initiating dexmedetomidine from her underlying disease rather than the effects of the sedative.

AB - Agents used to control end-of-life suffering are associated with troublesome side effects. The use of dexmedetomidine for sedation during withdrawal of support in pediatrics is not yet described. An adolescent female with progressive and irreversible pulmonary deterioration was admitted. Despite weeks of therapy, she did not tolerate weaning of supplemental oxygen or continuous bilevel positive airway pressure. Given her condition and the perception that she was suffering, the family requested withdrawal of support. Despite opioids and benzodiazepines, she appeared to be uncomfortable after support was withdrawn. Ketamine was initiated. Relief from ketamine was brief, and its use was associated with a “wide-eyed” look that was distressing to the family. Ketamine was discontinued and a dexmedetomidine infusion was initiated. The patient's level of comfort improved greatly. The child died peacefully 24 hours after initiating dexmedetomidine from her underlying disease rather than the effects of the sedative.

UR - http://www.scopus.com/inward/record.url?scp=85022214165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022214165&partnerID=8YFLogxK

U2 - 10.4137/PCRT.S27954

DO - 10.4137/PCRT.S27954

M3 - Article

C2 - 26339188

AN - SCOPUS:85022214165

VL - 9

SP - 15

EP - 18

JO - Palliative Care

JF - Palliative Care

SN - 1178-2242

ER -